Efficacy and safety of gemcitabine plus doxorubicin in patients with renal medullary carcinoma

Renal medullary carcinoma (RMC) is an extremely rare and aggressive form of kidney cancer. It is almost exclusively found in young people who carry the sickle cell gene. The sickle cell gene is particularly common in people with an African or Caribbean family background and can cause a group of inherited conditions that affect the red blood […]

read more

Survival after nephrectomy for various kidney cancer subtypes

Data presented at the American Urological Association (AUA) 2021 meeting last month shows that 5-year survival rates following partial or radical nephrectomy for renal cell carcinoma (RCC) vary depending on the histology of the RCC subtype. The results of this study have implications for developing personalised therapies to target high-risk, aggressive tumours. The researchers identified […]

read more

The evolution of kidney tumours

Some very interesting work has been coming out of the Francis Crick Institute in London about the evolution of kidney tumours. The research is being led by Dr Samra Turajlic who also works at the Royal Marsden Hospital in London and is one of KCSN’s trustees. Here is her explanation of this very exciting work: […]

read more

Patterns of metastases for clear cell, papillary and chromophobe RCC associated with survival

A recent study published in JAMA Network Open looked at the data from over 10,000 renal cell carcinoma (RCC) patients from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) and reported on the sites of metastases for three of the RCC subtypes and their survival outcomes. Metastases from clear cell RCC (9252 patients, 92%) […]

read more

VENUSS prognostic model for papillary kidney cancer

A recent study published in BMC Medicine this month investigates clinical and pathological variables and outcomes of 556 patients with papillary renal cell carcinoma (RCC) with the view to developing a scoring system to help predict the likely course of the disease in patients (a prognostic scoring system). The VENUSS prognostic score included the presence […]

read more

Hereditary kidney cancer – new syndromes

A recent review of the literature in European Urology summarises the preclinical and clinical data on hereditary renal cancer. There are several well-described hereditary renal cancer syndromes, such as von Hippel-Lindau disease (VHL), a hereditary syndrome that may lead to the development of renal cell carcinoma (RCC). Patients with VHL have a lifetime risk of […]

read more

Mucinous tubular and spindle cell carcinoma

A recent study, published in Clinical Genitourinary Cancer, looked at the clinical features, treatment outcomes and genetic profiles of patients with mucinous tubular and spindle-cell carcinoma (MTSCC), a rare type of kidney cancer. There were 25 patients in the study, most of which had asymptomatic low-grade and localised tumours. Six patients had metastatic disease. The […]

read more

Current perspectives on non-clear cell kidney cancer

The majority of kidney cancer (around 80%) is characterised as clear-cell renal cell carcinoma (RCC), while the remaining 20% is non-clear cell RCC. Most of these are papillary RCC, but non-clear cell RCC also includes collecting duct, translocation, chromophobe and a variety of other rare tumour types. Because non-clear cell RCC is relatively rare, data […]

read more

Clinical characteristics and genomic alterations associated with outcome in chromophobe RCC

A recent study by researchers in New York, USA, and published in Clinical Genitourinary Cancer identified gene alterations and clinical characteristics that could help predict outcome in patients with a rare form of renal cell carcinoma (RCC) called chromophobe RCC. These gene alterations and clinical characteristics could also help identify potential targeted therapy options in […]

read more

Syntaxin 6: A potential biomarker for papillary renal cell carcinoma

A recent study published in Scientific Reports last month has identified Syntaxin 6, a protein known to play an important role in the movement of protein and lipids within cells (intracellular trafficking), as a prognostic biomarker for patients with a type of kidney cancer called papillary renal cell carcinoma (RCC). Syntaxin 6 also holds promise […]

read more
Showing 1 to 10 of 20 results
  TOP